No Data
No Data
No Data
TLSA: 1H:21 Financial Update
By John Vandermosten, CFANASDAQ:TLSAREAD THE FULL TLSA RESEARCH REPORTFirst Half 2021 ResultsTiziana Life Sciences (NASDAQ:TLSA) updated on first half 2021 financial and operational results in a pres
PDL BioPharma indicates timeline for Nasdaq voluntarily delisting
PDL BioPharma (NASDAQ:PDLI) -3.9% PM, formally notified The Nasdaq of its intent to delist its common stock from the Nasdaq on or about Dec.28, 2020 and suspend trading prior to the Dec.31 market open
PDL Announces Timeline for Voluntarily Delisting from Nasdaq; Sets Date For Dec. 31, 2020
PDL Announces Timeline for Voluntarily Delisting from Nasdaq INCLINE VILLAGE, Nev., Dec. 8, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ:PDLI) today announced that it has
PDL BioPharma Liquidation May Offer 40% Upside For Patient Investors Comfortable With Illiquidity
SummaryPDLI is liquidating, it should delist from the NASDAQ on December 31, 2020.Patient investors can ultimately expect a return of approximately 40% based on net assets.The Glumetza royalties may be undervalued today based on arguably a punitive discount rate, creating closer to 60% upside under a 5% discount rate for the portfolio.There is downside risk too, from payments being pushed out years into the future, a class action related to Glumetza pricing and other uncertainties.On balance, PDLI presents an opportunity for patient investors capable of owning illiquid investments.
Recap: PDL BioPharma Q3 Earnings
Shares of PDL BioPharma (NASDAQ:PDLI) rose 7.96% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 211.11% year over year to ($0.10), whic
PDL BioPharma Q3 EPS $0.04 Misses $0.06 Estimate, Sales $4.12M Miss $5.50M Estimate
PDL BioPharma (NASDAQ:PDLI) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 33.33 percent. This is a 55.56 percent decrease over earnings of $0.0
No Data